Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy

F Pein, O Sakiroglu, M Dahan, J Lebidois, P Merlet, A Shamsaldin, E Villain, F de Vathaire, D Sidi, O Hartmann, F Pein, O Sakiroglu, M Dahan, J Lebidois, P Merlet, A Shamsaldin, E Villain, F de Vathaire, D Sidi, O Hartmann

Abstract

The purpose of this paper was to determine the cardiac status in children 15 years or more after adriamycin therapy for a solid tumour. Of the 447 pts, 229 pts were fully studied and 218 were not. The following cardiac evaluations were proposed to all the 447 consecutive patients (pts): (1) cardiac Doppler US by one of two expert cardiologists; (2) cardiac rhythm and conduction abnormalities including 24-hour holter ECG; (3) (131)l-mlBG myocardial scintigraphy; (4) serum brain natriuretic peptide levels at rest; (5) an exercise test with VO(2) max measurement. The radiation doses delivered to 6 points in the heart were estimated for all patients who had received radiotherapy. Congestive heart failure was diagnosed in 24 of 229 (10%) evaluated pts, with a median interval of 15 years (0.3-24 years) from the first symptom after adriamycin treatment. Among the 205 remaining pts, 13 asymptomatic pts (6%) had severe (n=4) (FS<20%) or marked (n=9) (20< or =FS<25%) systolic dysfunction. In the 192 others, the median meridional end-systolic wall stress was 91 (53-135) and it exceeded 100 g cm(-2) in 52 pts. Using a Cox model, only the cumulative dose of adriamycin and the average radiation dose to the heart, were identified as risk factors for a pathological cardiac status. In conclusion, the risk of cardiac failure or severe abnormalities increases with adriamycin treatment, radiotherapy and time since treatment, even after a follow-up of 15 years or more. In our series, after an average follow-up of 18 years, 39% of the children had a severe cardiac dysfunction or major ventricular overload conditions. The risk increases with the dose of adriamycin and radiation received to the heart, without evidence for threshold.

Figures

Figure 1
Figure 1
Risk of cardiac failure and time since anthracycline exposure.
Figure 2
Figure 2
Pressure to volume ratio, according to corrected left ventricular mass in female and male.

References

    1. Abraham R, Basser RL, Green MD (1996) A risk–benefit assessment of anthracyclines antibiotics in antineoplastic therapy. Drug Saf 15(6): 406–429
    1. Breslow NE, Day NE (1980) Statistical Methods in Cancer Research. The Analysis of Case–control Studies, Volume I. IARC Scientific Publications No. 32. France: Lyon. 350 pp
    1. Breslow NE, Day NE (1987) Statistical Methods in Cancer Research. The Design and Analysis of Cohort Studies, Volume II. IARC Scientific Publications No. 40. France: Lyon. 406 pp
    1. Bu'Lock FA, Mott MG, Oakhill A, Martin RP (1995) Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms and pathophysiology. Br Heart J 73: 340–350
    1. Diallo I, Lamon A, Shamsaldin A, Grimaud E, de Vathaire F, Chavaudra J (1996) Estimation of the radiation dose delivered to any point outside the target volume per patient treated with external beam radiotherapy. Radiother Oncol 38: 269–271
    1. Ganau A, Devereux RB, Pickering TG, Roman MJ, Schnall PL, Santucci S, Spitzer MC, Laragh JH (1990) Relation of ventricular haemodynamic load and contractile performance to left ventricular mass in hypertension. Circulation 81(1): 25–36
    1. Green DM, Grigoriev YA, Nan B, Takashima JR, Norkool PA, D'Angio GJ, Breslow NE (2001) Congestive heart failure after treatment for Wilms' tumour. A report from the National Wilms' Tumour Study Group. J Clin Oncol 19: 1926–1934
    1. Grenier MA, Lipshultz SE (1998) Epidemiology of anthracyclin cardiotoxicity in children and adults. Semin Oncol 25(Suppl 10): 72–85
    1. Hortobagyi GN (1997) Anthracyclines in the treatment of cancer: an overview. Drugs 54(Suppl 4): 1–7
    1. Kremer LCM, Van der Pal HJH, Offringa M, Van Dalen EC, Voute PA (2002) Frequency and risk factors of subclinical cardiotoxcity after anthracycline therapy in children: a systematic review. Ann Oncol 13: 819–829
    1. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukaemia C in childhood. N Engl J Med 324: 808–815
    1. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Salland SE, Sanders SP, Orav EJ, Gelber RD, Colan SD (1995) Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332: 1738–1743
    1. Nysom K, Holm K, Lipsitz SR, Mone SM, Colan SD, Orav EJ, Sallan SE, Olsen JH, Hertz H, Jacobsen JR, Lipshultz SE (1998) Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukaemia C. J Clin Oncol 16: 545–550
    1. Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22(4): 263–302
    1. Sallan SE, Clavell LA (1984) Cardiac effects of anthracyclines used in the treatment of childhood acute lymphoblastic leukaemia: a 10-year experience. Semin oncol 11(Suppl 3): 19–21
    1. Sandler H, Dodge HT (1963) Left ventricular tension and stress in man. Circ Res 13: 91–104
    1. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 2: 358–367
    1. Shamsaldin A, Grimaud E, Hardiman C, Diallo I, de-Vathaire F, Chavaudra J (1998) Dose distribution throughout the body from radiotherapy for Hodgkin's disease in childhood. Radiother Oncol 49: 85–90
    1. Silber JH, Jakacki RI, Larsen RL, Goldwein JW, Barber G (1993) Forecasting cardiac function after anthracyclines in childhood: the role of dose, age and gender. In Bricker JT, Green DM, D'Angio GJ (eds) Cardiac Toxicity after Treatment for Childhood Cancer, New York: Wiley-Liss, pp 95–192
    1. Sorensen K, Levitt G, Sebag-Montefiore D (1995) Cardiac function in Wilms' tumour survivors. J Clin Oncol 13: 1546–1556
    1. Sorensen K, Levitt G, Bull C, Chessells J, Sullivan I (1997) Anthracycline dose in childhood acute lymphoblastic leukaemia: issues of early survival versus late cardiotoxicity. J Clin Oncol 15: 61–98
    1. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy L (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266: 1672–1677
    1. Steinherz LJ, Steinherz PG, Tan CT, Heller G (1993) Anthracycline-related cardiac damage. In Bricker JT, Green DM, D'Angio GJ (eds) Cardiac Toxicity after Treatment for Childhood Cancer, New York: Wiley-Liss, pp 63–72
    1. Steinherz LJ, Steinherz PG, Tan CT (1995) Cardiac failure and dysrythmias 6–19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 24: 352–361
    1. Von Hoff DD, Layard MW, Basa P, Davis Jr HL, Von Hoff AL, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710–717

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel